ANAB stock forecast
Our latest prediction for AnaptysBio, Inc.'s stock price was made on the June 10, 2019 when the stock price was at 72.22$.
In the short term (2weeks), ANAB's stock price should outperform the market by 0.83%. During that period the price should oscillate between -6.78% and +8.51%.
In the medium term (3months), ANAB's stock price should outperform the market by 0.74%. During that period the price should oscillate between -15.19% and +26.20%.Get email alerts
Create a solid portfolio with ANAB
About AnaptysBio, Inc.
AnaptysBio, Inc. is a clinical stage biotechnology company, which engages in developing antibody product candidates focused on unmet medical needs in inflammation. Its products pipeline include ANB020, ANB019, and checkpoint receptor agonist antibodies. The company was founded by Andrew B. Cubitt, William J. Boyle and Nicholas B. Lydon in November 2005 and is headquartered in San Diego, CA.
At the moment the company generates 5M USD in revenues.
On its last earning announcement, the company reported a loss of -2.69$ per share.
The book value per share is 11.86$
Three months stock forecastJune 10, 2019
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|